Biomarin Pharmaceutical (BMRN) Receivables: 2009-2025
Historic Receivables for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $790.3 million.
- Biomarin Pharmaceutical's Receivables rose 1.64% to $790.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 billion, marking a year-over-year increase of 11.18%. This contributed to the annual value of $660.5 million for FY2024, which is 4.23% up from last year.
- As of Q3 2025, Biomarin Pharmaceutical's Receivables stood at $790.3 million, which was down 7.66% from $855.9 million recorded in Q2 2025.
- Over the past 5 years, Biomarin Pharmaceutical's Receivables peaked at $855.9 million during Q2 2025, and registered a low of $373.4 million during Q4 2021.
- Over the past 3 years, Biomarin Pharmaceutical's median Receivables value was $660.5 million (recorded in 2024), while the average stood at $687.8 million.
- In the last 5 years, Biomarin Pharmaceutical's Receivables declined by 16.72% in 2021 and then soared by 39.00% in 2023.
- Biomarin Pharmaceutical's Receivables (Quarterly) stood at $373.4 million in 2021, then increased by 23.55% to $461.3 million in 2022, then spiked by 37.37% to $633.7 million in 2023, then grew by 4.23% to $660.5 million in 2024, then rose by 1.64% to $790.3 million in 2025.
- Its Receivables was $790.3 million in Q3 2025, compared to $855.9 million in Q2 2025 and $739.2 million in Q1 2025.